Galera Therapeutics has dismutase mimetics. Innovation Pharmaceuticals (OTCQB: IPIX) has defensin mimetics. The two sciences are similar in looking to mimic natural processes of the body to prevent or treat disease. Each are addressing severe oral mucositis (SOM) in head and neck cancer patients with their respective flagship drug with hopes that it will spawn a blockbuster franchise.
There are many more similarities between these two companies that portend success and lend support to the notion that IPIX is arguably undervalued. This contention is underscored by clinical data as the two strive to bring their prophylactic SOM therapies to market.
Oral mucositis is a frequent and often debilitating side effect of chemotherapy or radiation characterized by ulcerations and infection of the oral mucosa. It can become so serious that parenteral …View the full post at: A Look at New Oral Mucositis Drugs: Galera Therapeutics Capital Raise Points to Innovation Pharmaceuticals Being Grossly Undervalued …
Related Articles:
5 Stocks To Watch As Cannabis Goes Global
The Secret Tech Which Could Transform Cannabis Markets
High-Profile Mergers and Acquisitions Showcase Cannabis Industry’s Race to Build Market Share
How A NASA Scientist Could Help Cannabis Industry Profits
